SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase III Clinical Trial for the Efficacy and Safety of Fugliglitinate Benzoate Tablets in Patients With Type 2 Diabetes Who Cannot be Effectively Controlled by Metformin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05801627
• Other study ID #: SAL067-C-008
• Secondary ID: CTR20200061ChiCT
• Status: Completed
• Phase: Phase 3
• Start date: May 6, 2020
• Est. completion date: May 24, 2022

Study information

• Verified date: March 2023
• Source: Shenzhen Salubris Pharmaceuticals Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is the phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and long-term safety of SAL067 in T2DM patients uncontrolled by metformin, comprising 24 weeks of double-blind treatment period followed by an open-label treatment period, making up a total of 52 weeks.

Description:

All eligible subjects would enter the 24 weeks of double-blind treatment period and were randomized into the SAL067 group (12 mg once daily) or placebo group at a 2:1:1 ratio. After 24 weeks of double-blind treatment, subjects would enter the extended open-label treatment period. Subjects in the placebo group were to be switched to SAL067 (12 mg once daily) treatment, while patients in the SAL067 groups continued the same treatment until the end of the whole 52 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 408
• Est. completion date: May 24, 2022
• Est. primary completion date: May 24, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Type 2 diabetes patients who meet the diagnostic criteria for diabetes issued by the World Health Organization (WHO) in 1999;

2. Men or women aged 18 to 75 years old at the day of signing the informed consent;

3. Body mass index: BMI 19kg/m2 to 35kg/m2, [BMI=weight (kg)/height 2 (m2)];

4. Subjects treated with metformin= 1500mg/day constantly for at least 8 consecutive weeks before screnning;

5. Glycated hemoglobin (HbA1c): Screening period: HbA1c 7.5% to 10.5% (tested by the research center), when randomly enrolled: HbA1c 7.0% to 10.0% (central laboratory test) Measurement);

6. Screening period and random time fasting blood glucose <=13.9mmol/L.

Exclusion Criteria:

1. Drug compliance during the introduction period <80% or >120%;

2. Use other hypoglycemic drugs other than test drugs during the introduction period;

3. The patient may have any contraindications, allergies or hypersensitivity to fuglitagliptin (including study drug and placebo) or its excipients, DPP4 drugs, metformin;

4. Before screening, have any of the following endocrine-related medical history or evidence:

• Diabetes other than type 2 diabetes, such as type 1 diabetes, single-gene mutation diabetes, diabetes caused by pancreatic injury or secondary diabetes, such as diabetes caused by Cushing's syndrome or acromegaly;

• diabetic ketoacidosis, hyperglycemia and hyperosmolarity, lacticacidosis and other acute complications of diabetes within 6 months before screening;

• severe hypoglycemia episodes (such as sleepiness caused by hypoglycemia, unconsciousness, nonsense, and even coma), or a serious history of unconscious hypoglycemia;

5. Before screening, there is a history or evidence of any of the following diseases:

• Unstable angina, stroke or transient ischemic attack, myocardial infarction, coronary artery bypass graft or percutaneous coronary intervention (diagnostic angiography is allowed of);

• Decompensated heart failure before screening (New York Heart Association NYHA heart function grades III and IV, persistent and clinically significant arrhythmia;

• A history of acute and chronic pancreatitis, symptomatic gallbladder disease or history of pancreatic injury, etc. may lead to high risk factors for pancreatitis.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• SAL067
SAL067 6mg(2 tablet) and Metformin =1500mg
• Placebo
Placebo (2 tablet) and Metformin =1500mg

Locations

Country	Name	City	State
China	Peking University Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HbA1c change from baseline at week 24	Change From Baseline in Hemoglobin A1c (HbA1c) at week 24	Baseline and week 24
Secondary	HbA1c change from baseline at week 4,week 12,week 40 and week 52	Change From Baseline in Hemoglobin A1c (HbA1c) at week 4,week 12,week 40 and week 52	Baseline, week 4, week 12, week 40 and week 52
Secondary	FPG change from baseline at week 4, week 8, week 12, week 16, week 24, week 40 and week 52		Baseline, week 4, week 8, week 12, week 24, week 40 and week 52
Secondary	Percentage of patients with HbA1c <7.0% and HbA1c <6.5% at week 24 and week 52		Baseline, week 24 and week 52
Secondary	Percentage of patients required use of rescue therapy at week 24 and week 52		Baseline, week 24 and week 52
Secondary	Fasting c-peptide change from baseline at week 24 and week 52		Baseline, week 24 and week 52
Secondary	Insulin sensitivity change (calculated by HOMA-IS) from baseline at week 24 and week 52		Baseline, week 24 and week 52
Secondary	eatic ß-cell function change (calculated by HOMA-ß ) from baseline at week 24 and week 52		Baseline, week 24 and week 52